TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25615707

Group type: EXPERIMENTAL
Intervention: FUEL Your Life intervention
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 362
Study: 25012565

Group type: EXPERIMENTAL
Intervention: IFN+GM-CSF
Number of subjects: 58
Study: 22958354

Group type: EXPERIMENTAL
Intervention: Comprehensive Health Assessment Program (CHAP), a one-off health check, and the Ask Health Diary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education component of the intervention delivered as part of the school curriculum
Number of subjects: 0
Study: 20856184

Group type: EXPERIMENTAL
Intervention: venlafaxine extended release (75 to 325 mg daily)
Number of subjects: 161
Study: 17586338

Group type: EXPERIMENTAL
Intervention: Distraction-based coping leaflet
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard information (Control)
Number of subjects: 162
Study: 16292117

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 15
Study: 11809349

Group type: EXPERIMENTAL
Intervention: Initial medical management
Number of subjects: 733
Study: 10189453

Group type: EXPERIMENTAL
Intervention: Fat-saturated images
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Digital image subtraction
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Anticholinergic agent
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High-caloric meal
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 140
Study: 7756056

Group type: EXPERIMENTAL
Intervention: GnRH analogs
Number of subjects: 21

Group type: COMPARATOR
Intervention: GnRH analogs + Org OD 14 (Tibolone, Livial)
Number of subjects: 21
Study: 1326708

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate (E2V)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 2 mg oestradiol valerate combined with 1 mg cyproterone acetate (E2V+CPA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 2860453

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (detuned SWD)
Number of subjects: 109
Study: 29208679

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (150 million)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Microvascular obstruction present at baseline
Number of subjects: 120
Study: 27501599

Group type: EXPERIMENTAL
Intervention: Nasal Cannula 4 liters per minute
Number of subjects: 500

Group type: COMPARATOR
Intervention: Oxygen Mask 5 liters per minute
Number of subjects: 500
Study: 26999966

Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids (40 mg methylprednisolone)
Number of subjects: 0
Study: 23113988

Group type: EXPERIMENTAL
Intervention: Predischarge home visit
Number of subjects: 126

Group type: COMPARATOR
Intervention: Structured, hospital-based interview (Control)
Number of subjects: 126
Study: 21252702

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g/kg body weight)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18288974

Group type: EXPERIMENTAL
Intervention: zidovudine+lamivudine+lopinavir/ritonavir
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: tenofovir+lamivudine+efavirenz
Number of subjects: 64
Study: 17063660

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-particle formulations of ICSs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid conjugation of ICSs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICS with longer serum half-life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICS with increased protein binding and high systemic clearance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced oropharyngeal deposition and prodrug administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ideal ICS characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICS with high plasma protein binding and rapid clearance
Number of subjects: 0
Study: 14499200

Group type: EXPERIMENTAL
Intervention: Wheeled walker
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Standard walker
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unassisted walking
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Wheeled walker with laser attachment
Number of subjects: 19
Study: 10953973

Group type: EXPERIMENTAL
Intervention: Biweekly CHOP (8 cycles)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dose-escalated CHOP (6 cycles with cyclophosphamide 1.5 g/m2 and doxorubicin 70 mg/m2)
Number of subjects: 63
Study: 9543399

Group type: EXPERIMENTAL
Intervention: HAB (tissue adhesive)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HAB
Number of subjects: 61
Study: 8181400

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise program (Group 2) for five weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 26
Study: 3286363

Group type: EXPERIMENTAL
Intervention: 200 mg of acarbose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29685011

Group type: EXPERIMENTAL
Intervention: Glucocorticoids in combination with ursodesoxycholic acid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Glucocorticoids only (Control)
Number of subjects: 120
Study: 27533307

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 24884779

Group type: EXPERIMENTAL
Intervention: Personalized Prevention Approach for CardioMetabolic Risk (PPA CMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 22490643

Group type: EXPERIMENTAL
Intervention: Nystatin prophylaxis
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study: 19888948

Group type: EXPERIMENTAL
Intervention: C.E.R.A. once every 4 weeks (Q4W)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: C.E.R.A. twice every week (Q2W)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Darbepoetin alfa (once weekly or Q2W)
Number of subjects: 296
Study: 18829800

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 60
Study: 16102549

Group type: EXPERIMENTAL
Intervention: NuvaRing (15 microg EE/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermal patch (20 microg EE/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined oral contraceptive (30 microg EE)
Number of subjects: 0
Study: 11880765

Group type: EXPERIMENTAL
Intervention: Intervention group using diaries to measure sunscreen application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not using diaries
Number of subjects: 0
Study: 7631288

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) administered orally while fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) administered orally after a standard meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) administered intravenously
Number of subjects: 12
Study: 2921098

Group type: EXPERIMENTAL
Intervention: Simvastatin (MK 733) 20 mg and 40 mg daily for 104 weeks
Number of subjects: 19
Study: 31904749

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia along with general anaesthesia
Number of subjects: 101

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 101
Study: 28348100

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate, neutral‐pH, low‐GDP PD fluid (Physioneal)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard lactate‐buffered PD fluid (Dianeal)
Number of subjects: 78
Study: 26706793

Group type: EXPERIMENTAL
Intervention: Video fluoroscopy
Number of subjects: 50
Study: 23543341

Group type: EXPERIMENTAL
Intervention: Group exercise training (12-week program under supervision)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 99
Study: 22132709

Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Povidone iodine plus bepanthenol cream (standard practice)
Number of subjects: 211
Study: 19240683

Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (lymphatic application)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard lymphatic drainage
Number of subjects: 24
Study: 17976098

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 195
Study: 15089819

Group type: EXPERIMENTAL
Intervention: tolterodine (2 mg, BID) + duloxetine (40 mg, BID)
Number of subjects: 16

Group type: COMPARATOR
Intervention: tolterodine (2 mg, BID) + duloxetine placebo (BID)
Number of subjects: 16
Study: 11573019

Group type: EXPERIMENTAL
Intervention: 2-hour biweekly training sessions for 1 year (total 60 hours) for managers
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 302
Study: 9587128

Group type: EXPERIMENTAL
Intervention: Zinc sulfate tablets (45 mg, three times a day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo tablets (three times a day)
Number of subjects: 18
Study: 7888741

Group type: EXPERIMENTAL
Intervention: Pacemakers on
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pacemakers off or turned to minimum rate
Number of subjects: 11
Study: 2669092

Group type: EXPERIMENTAL
Intervention: 1.2 g L-tryptophan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.4 g L-tryptophan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-tryptophan (both doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-tryptophan (all doses)
Number of subjects: 10
Study: 796836

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1015
Study: 31309975

Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 370
Study: 31090869

Group type: EXPERIMENTAL
Intervention: Implantable pulmonary artery pressure monitoring system
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1087
Study: 28282524

Group type: EXPERIMENTAL
Intervention: Preventure intervention (2-session coping skills intervention)
Number of subjects: 699

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 699
Study: 26366068

Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23903649

Group type: EXPERIMENTAL
Intervention: Casein‐phosphopeptide amorphous‐calcium‐phosphate (CPP‐ACP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glass-ionomer (GI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (original‐lesion control, intra‐oral controls)
Number of subjects: 0
Study: 22153532

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 g bid for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sodium bicarbonate 1 g bid for 10 days)
Number of subjects: 0
Study: 19898719

Group type: COMPARATOR
Intervention: Acetone-containing bonding agent (control group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 146

Group type: COMPARATOR
Intervention: 37% orthophosphoric acid (control group)
Number of subjects: 146
Study: 17998456

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg twice daily (group 1)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg twice daily (group 2)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Warfarin continued (group 3)
Number of subjects: 355
Study: 14726422

Group type: EXPERIMENTAL
Intervention: Glutathione aerosol (300 or 450 mg, thrice daily for 14 days)
Number of subjects: 23
Study: 12487386

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapies prescribed as part of the trial
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Adverse clinical events (e.g., dermatological, gastrointestinal symptoms)
Number of subjects: 93
Study: 9772328

Group type: EXPERIMENTAL
Intervention: Concomitant vaccination (both vaccines administered simultaneously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined vaccine (single injection of both vaccines mixed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monovalent vaccines (each vaccine administered alone)
Number of subjects: 0
Study: 8209214

Group type: EXPERIMENTAL
Intervention: Scaling and root planing with sharp instruments combined with pocket flushing
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scaling with blunt plastic curettes and pocket flushing
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pocket flushing alone
Number of subjects: 8
Study: 2590611

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg intravenous)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sodium salicylate (600 mg intravenous)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (control for aspirin infusion)
Number of subjects: 9
Study: 184978

Group type: EXPERIMENTAL
Intervention: ACTH gel (80 units once weekly or 80 units twice weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 31610099

Group type: EXPERIMENTAL
Intervention: Test drug (10 mg rivaroxaban tablet)
Number of subjects: 28
Study: 31331789

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg up to 150 mg every 2 weeks for COMBO I & II or 150 mg every 2 weeks for LONG TERM)
Number of subjects: 4489

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4489

Group type: COMPARATOR
Intervention: Control (placebo for COMBO I and LONG TERM or ezetimibe for COMBO II)
Number of subjects: 4489
Study: 28481893

Group type: EXPERIMENTAL
Intervention: Transdiagnostic psychodynamic online intervention (12 weeks)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control group (augmented treatment as usual)
Number of subjects: 664
Study: 25920961

Group type: EXPERIMENTAL
Intervention: Argon gas device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid nitrogen device
Number of subjects: 0
Study: 23970700

Group type: EXPERIMENTAL
Intervention: HSV-1
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: HSV-2
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: Both HSV-1 and HSV-2
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: Seronegativity to both HSV-1 and HSV-2
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: Age and racial differences
Number of subjects: 2694
Study: 21777735

Group type: EXPERIMENTAL
Intervention: Fipronil, amitraz and (S)-methoprene (CERTIFECT™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated dogs)
Number of subjects: 0
Study: 19195785

Group type: EXPERIMENTAL
Intervention: CR-oxycodone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 17037953

Group type: EXPERIMENTAL
Intervention: Self-selected music listening intervention delivered by a board‐certified music therapist
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 63
Study: 12643328

Group type: EXPERIMENTAL
Intervention: PEG-Hirudin (i.v. bolus of 0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Number of subjects: 15

Group type: COMPARATOR
Intervention: ASA (325 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined administration of ASA and PEG-Hirudin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PEG-Hirudin alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PEG-Hirudin (0.2 mg/kg + 0.02 mg/kg/h for 24 hours)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined use of PEG-Hirudin and ASA
Number of subjects: 15
Study: 10704630

Group type: EXPERIMENTAL
Intervention: Patients with 0% stenosis
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Patients with 10‐69% stenosis
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Patients with 70‐100% stenosis
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Patients under 70 years of age
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Catheterized patients
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Non‐smoking controls without angina
Number of subjects: 1200
Study: 9344296

Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS) ambulation training sessions using the Parastep 1 system (32 sessions)
Number of subjects: 16
Study: 10124337

Group type: EXPERIMENTAL
Intervention: Specialized physical therapists
Number of subjects: 26
Study: 3748494

Group type: EXPERIMENTAL
Intervention: Ampicillin sodium
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Cephapirin sodium
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Cefamandole nafate
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Moxalactam disodium
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 360
Study: 29753888

Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled knee (MPK, Kenevo, Otto Bock)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-Microprocessor-controlled knees (NMPKs)
Number of subjects: 35
Study: 27438104

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 1830
Study: 24912063

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional vocational services (Control)
Number of subjects: 37
Study: 22300506

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 mcg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 mcg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 mcg/day and 1000 mcg/day
Number of subjects: 22
Study: 20191468

Group type: EXPERIMENTAL
Intervention: Internet-based intervention to promote physical activity (PA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control waiting-list group
Number of subjects: 33
Study: 17070997

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15598978

Group type: EXPERIMENTAL
Intervention: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard schedule (375 mg/m2 weekly x 4) followed by no further treatment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Prolonged rituximab administration (375 mg/m2 every 8 weeks for four times) in pretreated patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard schedule (375 mg/m2 weekly x 4) in pretreated patients
Number of subjects: 104
Study: 11777366

Group type: EXPERIMENTAL
Intervention: Long-term very low doses of prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: High doses of prednisone
Number of subjects: 0
Study: 9504939

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg every eight hours)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Sucralfate (1 g every six hours)
Number of subjects: 1200
Study: 8541559

Group type: EXPERIMENTAL
Intervention: Hetastarch (HS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pentastarch (PS)
Number of subjects: 36
Study: 2112812

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin
Number of subjects: 52
Study: 391210

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30047013

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 72
Study: 27651067

Group type: EXPERIMENTAL
Intervention: real iTBS
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 25888137

Group type: EXPERIMENTAL
Intervention: Simultaneous retrograde intrarenal surgery (RIRS)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ureteroscopy alone
Number of subjects: 144
Study: 23953605

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day) + imidafenacin (0.1 mg 2 times a day)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg/day) alone
Number of subjects: 308
Study: 21840681

Group type: EXPERIMENTAL
Intervention: Vertical orientation of plate-haptic IOLs (Akreos Adapt)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Horizontal orientation of plate-haptic IOLs (Akreos Adapt)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1-piece IOLs (Acrysof SA60AT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3-piece IOLs (Acrysof MA60AC)
Number of subjects: 30
Study: 19174069

Group type: EXPERIMENTAL
Intervention: Enteral diet supplements with arginine (group I)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II)
Number of subjects: 41
Study: 16306030

Group type: COMPARATOR
Intervention: Regimen A (nelfinavir, stavudine, didanosine, twice-daily)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Regimen B (nevirapine, didanosine, lamivudine, once-daily)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Regimen C (saquinavir, ritonavir, didanosine, lamivudine, once-daily)
Number of subjects: 71
Study: 12431858

Group type: EXPERIMENTAL
Intervention: tryptophan-free mixture of amino acids
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 10609977

Group type: EXPERIMENTAL
Intervention: Quit group (smoking abstinence)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Continuing-to-smoke control group
Number of subjects: 56
Study: 7582277

Group type: EXPERIMENTAL
Intervention: Single dose of 360 mg triamcinolone intramuscularly
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo triamcinolone followed by low-dose oral methotrexate (7.5 mg followed by 15 mg weekly)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo triamcinolone with placebo methotrexate
Number of subjects: 19